Use-Dependent Inhibition of Synaptic Transmission by the Secretion of Intravesicularly Accumulated Antipsychotic Drugs

Neuron

Volumn 74, Issue 5, 2012, Pages 830-844

  Tischbirek, Carsten H ^a   Wenzel, Eva M ^a,d,e   Zheng, Fang ^a   Huth, Tobias ^a   Amato, Davide ^a   Trapp, Stefan ^b   Denker, Annette ^c   Welzel, Oliver ^a   Lueke, Katharina ^a   Svetlitchny, Alexei ^a   Rauh, Manfred ^a   Deusser, Janina ^a   Schwab, Annemarie ^a   Rizzoli, Silvio O ^c   Henkel, Andreas W ^a,f   Müller, Christian P ^a   Alzheimer, Christian ^a   Kornhuber, Johannes ^a   Groemer, Teja W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c EUROPEAN NEUROSCIENCE INSTITUTE   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RELEASE; ELECTRON MICROSCOPY; EXOCYTOSIS; EXTRACELLULAR SPACE; HIPPOCAMPUS; IN VIVO STUDY; MICRODIALYSIS; MICROSCOPY; NERVE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE; SYNAPTIC INHIBITION;

AMINES; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BIOPHYSICS; CELLS, CULTURED; COMPUTER SIMULATION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; ENDOCYTOSIS; EXOCYTOSIS; GREEN FLUORESCENT PROTEINS; HIPPOCAMPUS; HYDROGEN-ION CONCENTRATION; MALE; MEMBRANE POTENTIALS; MICE; MICRODIALYSIS; MICROSCOPY, ELECTRON; MODELS, NEUROLOGICAL; NEUROBLASTOMA; NEURONS; PATCH-CLAMP TECHNIQUES; PYRIDINIUM COMPOUNDS; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SEROTONIN; SODIUM CHANNEL BLOCKERS; SYNAPSES; SYNAPTIC TRANSMISSION; SYNAPTIC VESICLES; TETRODOTOXIN; TIME FACTORS; TRANSFECTION;

EID: 84861957994     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2012.04.019     Document Type: Article

References (60)

1. Adie E.J., Kalinka S., Smith L., Francis M.J., Marenghi A., Cooper M.E., Briggs M., Michael N.P., Milligan G., Game S. A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques 2002, 33:1152-1154. 1156-1157.
2. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1235.
3. Amato D., Natesan S., Yavich L., Kapur S., Müller C.P. Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. Int. J. Neuropsychopharmacol. 2011, 14:1327-1339.
4. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Müller-Oerlinghausen B., Rao M.L., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265. Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie.
5. Chen H.T., Kandasamy S.B. Effect of chloral hydrate on in vivo KCl-induced striatal dopamine release in the rat. Neurochem. Res. 1996, 21:695-700.
6. Conti F., Gheri A., Pusch M., Moran O. Use dependence of tetrodotoxin block of sodium channels: a revival of the trapped-ion mechanism. Biophys. J. 1996, 71:1295-1312.
7. de Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 1974, 23:2495-2531.
8. Denker A., Kröhnert K., Rizzoli S.O. Revisiting synaptic vesicle pool localization in the Drosophila neuromuscular junction. J. Physiol. 2009, 587:2919-2926.
9. Dorostkar M.M., Dreosti E., Odermatt B., Lagnado L. Computational processing of optical measurements of neuronal and synaptic activity in networks. J. Neurosci. Methods 2010, 188:141-150.
10. Duvvuri M., Gong Y., Chatterji D., Krise J.P. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J. Biol. Chem. 2004, 279:32367-32372.
11. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Möller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 2005, 6:132-191.
12. Ferrarelli F., Peterson M.J., Sarasso S., Riedner B.A., Murphy M.J., Benca R.M., Bria P., Kalin N.H., Tononi G. Thalamic dysfunction in schizophrenia suggested by whole-night deficits in slow and fast spindles. Am. J. Psychiatry 2010, 167:1339-1348.
13. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349:1738-1749.
14. Gallinat J., Winterer G., Herrmann C.S., Senkowski D. Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing. Clin. Neurophysiol. 2004, 115:1863-1874.
15. Gee K.R., Brown K.A., Chen W.N., Bishop-Stewart J., Gray D., Johnson I. Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium 2000, 27:97-106.
16. Gemperle A.Y., Enz A., Pozza M.F., Lüthi A., Olpe H.R. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 2003, 117:681-695.
17. Goto Y., Yang C.R., Otani S. Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders. Biol. Psychiatry 2010, 67:199-207.
18. Groemer T.W., Klingauf J. Synaptic vesicles recycling spontaneously and during activity belong to the same vesicle pool. Nat. Neurosci. 2007, 10:145-147.
19. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005, 10:40-68.
20. Hu W., Tian C., Li T., Yang M., Hou H., Shu Y. Distinct contributions of Na(v)1.6 and Na(v)1.2 in action potential initiation and backpropagation. Nat. Neurosci. 2009, 12:996-1002.
21. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
22. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
23. Kellendonk C. Modeling excess striatal D2 receptors in mice. Prog. Brain Res. 2009, 179:59-65.
24. Koester H.J., Johnston D. Target cell-dependent normalization of transmitter release at neocortical synapses. Science 2005, 308:863-866.
25. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zöchling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. Am. J. Psychiatry 1999, 156:885-890.
26. Kornhuber J., Weigmann H., Röhrich J., Wiltfang J., Bleich S., Meineke I., Zöchling R., Härtter S., Riederer P., Hiemke C. Region specific distribution of levomepromazine in the human brain. J. Neural Transm. 2006, 113:387-397.
27. Kornhuber J., Henkel A.W., Groemer T.W., Städtler S., Welzel O., Tripal P., Rotter A., Bleich S., Trapp S. Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system. J. Cell. Physiol. 2010, 224:152-164.
28. Korpi E.R., Kleinman J.E., Costakos D.T., Linnoila M., Wyatt R.J. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res. 1984, 11:259-269.
29. Leipold E., Hansel A., Borges A., Heinemann S.H. Subtype specificity of scorpion beta-toxin Tz1 interaction with voltage-gated sodium channels is determined by the pore loop of domain 3. Mol. Pharmacol. 2006, 70:340-347.
30. Leucht S., Busch R., Hamann J., Kissling W., Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 2005, 57:1543-1549.
31. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31:234-242.
32. Lorincz A., Nusser Z. Cell-type-dependent molecular composition of the axon initial segment. J. Neurosci. 2008, 28:14329-14340.
33. Miesenböck G., De Angelis D.A., Rothman J.E. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 1998, 394:192-195.
34. Oertner T.G., Sabatini B.L., Nimchinsky E.A., Svoboda K. Facilitation at single synapses probed with optical quantal analysis. Nat. Neurosci. 2002, 5:657-664.
35. Ogata N., Yoshii M., Narahashi T. Psychotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res. 1989, 476:140-144.
36. Oshima I., Mino Y., Inomata Y. Institutionalisation and schizophrenia in Japan: social environments and negative symptoms: nationwide survey of in-patients. Br. J. Psychiatry 2003, 183:50-56.
37. Pum M.E., Huston J.P., De Souza Silva M.A., Müller C.P. Visual sensory-motor gating by serotonin activation in the medial prefrontal and occipital, but not in the rhinal, cortices in rats. Neuroscience 2008, 153:361-372.
38. Rayport S., Sulzer D. Visualization of antipsychotic drug binding to living mesolimbic neurons reveals D2 receptor, acidotropic, and lipophilic components. J. Neurochem. 1995, 65:691-703.
39. Royeck M., Horstmann M.T., Remy S., Reitze M., Yaari Y., Beck H. Role of axonal NaV1.6 sodium channels in action potential initiation of CA1 pyramidal neurons. J. Neurophysiol. 2008, 100:2361-2380.
40. Sah D.W., Bean B.P. Inhibition of P-type and N-type calcium channels by dopamine receptor antagonists. Mol. Pharmacol. 1994, 45:84-92.
41. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S " Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
42. Sankaranarayanan S., Ryan T.A. Calcium accelerates endocytosis of vSNAREs at hippocampal synapses. Nat. Neurosci. 2001, 4:129-136.
43. Sankaranarayanan S., De Angelis D., Rothman J.E., Ryan T.A. The use of pHluorins for optical measurements of presynaptic activity. Biophys. J. 2000, 79:2199-2208.
44. Sbalzarini I.F., Koumoutsakos P. Feature point tracking and trajectory analysis for video imaging in cell biology. J. Struct. Biol. 2005, 151:182-195.
45. Schikorski T., Stevens C.F. Quantitative ultrastructural analysis of hippocampal excitatory synapses. J. Neurosci. 1997, 17:5858-5867.
46. Schiller J., Schiller Y., Clapham D.E. NMDA receptors amplify calcium influx into dendritic spines during associative pre- and postsynaptic activation. Nat. Neurosci. 1998, 1:114-118.
47. Schmalzing G. The role of a transmembrane pH gradient in uptake and release of imipramine and haloperidol in synaptosomes. Mol. Pharmacol. 1988, 34:888-895.
48. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
49. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 2001, 53:119-133.
50. Sulzer D. How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 2011, 69:628-649.
51. Threadgill R., Bobb K., Ghosh A. Regulation of dendritic growth and remodeling by Rho, Rac, and Cdc42. Neuron 1997, 19:625-634.
52. Tost H., Meyer-Lindenberg A. Puzzling over schizophrenia: schizophrenia, social environment and the brain. Nat. Med. 2012, 18:211-213.
53. Trapp S., Rosania G.R., Horobin R.W., Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 2008, 37:1317-1328.
54. Tsuneizumi T., Babb S.M., Cohen B.M. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol. Psychiatry 1992, 32:817-824.
55. Uhlhaas P.J., Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat. Rev. Neurosci. 2010, 11:100-113.
56. Uhlhaas P.J., Linden D.E., Singer W., Haenschel C., Lindner M., Maurer K., Rodriguez E. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J. Neurosci. 2006, 26:8168-8175.
57. Wakamori M., Kaneda M., Oyama Y., Akaike N. Effects of chlordiazepoxide, chlorpromazine, diazepam, diphenylhydantoin, flunitrazepam and haloperidol on the voltage-dependent sodium current of isolated mammalian brain neurons. Brain Res. 1989, 494:374-378.
58. Welzel O., Henkel A.W., Stroebel A.M., Jung J., Tischbirek C.H., Ebert K., Kornhuber J., Rizzoli S.O., Groemer T.W. Systematic heterogeneity of fractional vesicle pool sizes and release rates of hippocampal synapses. Biophys. J. 2011, 100:593-601.
59. Yang T.T., Wang S.J. Effects of haloperidol and clozapine on glutamate release from nerve terminals isolated from rat prefrontal cortex. Synapse 2005, 56:12-20.
60. Zhang X., Zheng N., Zou P., Zhu H., Hinestroza J.P., Rosania G.R. Cells on pores: a simulation-driven analysis of transcellular small molecule transport. Mol. Pharm. 2010, 7:456-467.